甲状腺乳头状癌18F-FDG PET/CT显像葡萄糖代谢与BRAF突变的相关性研究

doi:10.11904/j.issn.1002-3070.2017.06.007

摘要/Abstract

摘要： 目的评估甲状腺乳头状癌(Papillary thyroid carcinoma,PTC)患者¹⁸F-FDG PET/CT的最大标准摄取值(SUV_max)与BRAF突变的相关性。方法回顾性分析我院在甲状腺切除术前接受¹⁸F-FDG PET/CT显像和活检的患者51例(平均年龄为49.3±12.9岁),病理诊断为PTC 48例,甲状腺滤泡状癌(Follicular thyroid carcinoma,FTC)3例。采用基因检测法检测BRAF V600E突变状态,半定量分析法测定甲状腺结节灶的SUV_max,分析患者临床资料包括性别、年龄、肿瘤大小和甲状腺球蛋白浓度与SUV_max之间的相关性;将患者分为BRAF V600E突变组和未突变组,分析比较两组间SUV_max值的差异。结果在PTC患者中,33例患者肿瘤发生BRAF V600E突变,15例患者肿瘤未发生突变,BRAF V600E突变组的SUV_max显著高于未突变组(5.5±3.9 vs. 2.2±1.2,P=0.002);肿瘤直径≥1cm的患者的SUV_max明显高于肿瘤＜1cm(P＜0.05);甲状腺球蛋白浓度升高患者的SUV_max高于正常甲状腺球蛋白浓度的患者(P＜0.05);FTC组中未观察到BRAF V600E突变。结论 PTC患者携带BRAF V600E突变基因相对于未携带者具有更高的SUV_max值,不同肿瘤大小、血清甲状腺球蛋浓度的PTC患者SUV_max值存在统计学差异。

关键词: ¹⁸F-FDG PET/CT, 甲状腺乳头状癌, 最大标准摄取值, BRAF突变

Abstract: Objective The of this study was to evaluate the correlation between maximum standard uptake values(SUV_max)of ¹⁸F-FDG PET/CT and BRAF mutation in patients with papillary thyroid carcinoma(PTC).Methods A total of 51 patients(mean age of 49.3±12.9 years)who underwent ¹⁸F-FDG PET /CT imaging and biopsy before thyroidectomy were retrospectively analyzed.Based on the pathological results,there were 48 patients with PTC and 3 patients with follicular thyroid carcinoma(FTC).The SUV_max of thyroid nodule was measured by semi-quantitative analysis.The correlation between clinical data(gender,age,tumor size and thyroglobulin concentration)and SUV_max was also analyzed.The difference of SUV_max between the two groups was analyzed by comparing the BRAF V600E mutation group and the non-mutation group.Results In patients with PTC,27 patients had BRAF V600E mutations and 11 patients had no tumor mutation.The SUV_max of BRAF V600E mutation group was significantly higher than that in the non-mutated group(5.5±3.9 vs. 2.2±1.2,P=0.002).The SUV_max of patients with tumor diameter ≥ 1cm was significantly higher than that in patients with tumor ＜1cm(P＜0.05).The SUV_max of patients with elevated thyroglobulin concentration was higher than that in normal patients(P＜0.05).No BRAF V600E mutation was observed in the FTC group.Conclusion The BRAF V600E mutant gene has a high SUV_max value in patients with PTC.There were significant difference in SUV_max among different tumor size and serum thyroglobulin concentration.

Key words: ¹⁸F-FDG PET/CT, Thyroid papillary carcinoma, Maximal standard uptake value, BRAF mutation

中图分类号:

R736.1

王治国, 武晓丹, 战莹, 张彤, 张国旭. 甲状腺乳头状癌¹⁸F-FDG PET/CT显像葡萄糖代谢与BRAF突变的相关性研究[J]. 实用肿瘤学杂志, 2017, 31(6): 519-523.

WANG Zhiguo, WU Xiaodan, ZHAN Ying, ZHANG Tong, ZHANG Guoxu. The correlation between glucose metabolism and BRAF mutation in ¹⁸F-FDG PET/CT imaging of papillary thyroid carcinoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 519-523.

参考文献

1 Tang KT,Lee CH.BRAF mutation in papillary thyroid carcinoma:pathogenic role and clinical implications[J].J Chin Med Assoc,2010,73(3):113-128.
2 Pak K,Kim SJ,Kim IJ,et al.The role of ¹⁸F-fluorodeoxyglucose positron emission tomography in differentiated thyroid cancer before surgery[J].Endocr Relat Cancer,2013,20(4):203-213.
3 Sturgeon C,Angelos P.Identification and treatment of aggressive thyroid cancers.Part 2:risk assessment and treatment[J].Oncology,2006,20(3):397-404.
4 Randolph GW,Duh QY,Heller KS,et al.The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes,as well as the presence of extranodal extension[J].Thyroid,2012,22(11):1144-1152.
5 薛明媚,刘保平,谢新立,等.¹⁸F-FDG PET/CT检测Tg阳性而¹³¹I-诊断剂量全身显像阴性分化型甲状腺癌患者复发和转移[J].中国医学影像技术,2016,32(2):218-222.
6 Gao WL,Wei LL,Chao YG,et al.Prognostic prediction of BRAF(V600E)and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas[J].Clin Lab,2012,58(9):919-926.
7 Rosenbaum-Krumme SJ,Gorges R,Bockisch A,et al.¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy[J].Eur J Nucl Med Mol Imaging,2012,39(9):1373-1380.
8 Li YJ,Dai YL,Cheng YS,et al.Positron emission tomography(18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma:A meta-analysis[J].Eur J Surg Oncol,2016,42(8):1103-1114.
9 Parmenter TJ,Kleinschmidt M,Kinross KM,et al.Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis[J].Cancer Discov,2014,4(4):423-433.
10 Normanno N,Rachiglio AM,Lambiase M,et al.Heterogeneity of KRAS,NRAS,BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial[J].Ann Oncol,2015,26(8):1710-1714.
11 Xing M,Alzahrani AS,Carson KA,et al.Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J].JAMA,2013,309(14):1493-1501.
12 Rosenbaum-Krumme SJ,Gǒrges R,Bockisch A,et al.¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy[J].Eur J Nucl Med Mol Imaging,2012,39(9):1373-1380.
13 Schulten HJ,Al-Maghrabi J,Al-Ghamdi K,et al.Mutational screening of RET,HRAS,KRAS,NRAS,BRAF,AKT1,and CTNNB1 in medullary thyroid carcinoma[J].Anticancer Res,2011,31(12):4179-4183.
14 Leenhardt L,Grosclaud P,Cherie-challine L,et al.Increased incidence of thyroid carcinoma in france:a true epidemic or thyroid nodule management effects? Report from the French thyroid cancer committee[J].Thyroid,2004,14(12):1056-1060.
15 Ward PS,Thompson CB.Metabolic reprogramming:a cancer hallmark even Warburg did not anticipate[J].Cancer Cell,2012,21(3):297-308.
16 Israel O,Yefremov N,Bar-Shalom R,et al.PET/CT detection of unexpected gastrointestinal foci of ¹⁸F-FDG uptake:incidence,localization patterns,and clinical significance[J].Cancer Cell,2012,21(3):297-308.
17 Ward PS,Thompson CB.Metabolic reprogramming:a cancer hallmark even Warburg did not anticipate[J].Cancer Cell,2012,21(3):297-308.
18 Parmenter TJ,Kleinschmidt M,Kinross KM,et al.Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis[J].Cancer Discov,2014,4(4):423-433.
19 Palaskas N,Larson SM,Schultz N,et al.¹⁸F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers[J].Cancer Res,2011,71(5):5164-5174.
20 Lee MH,Lee SE,Kim DW,et al.Mitochondrial localization and regulation of BRAFV600E in thyroid cancer:a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAF V600E[J].J Clin Endocrinol Metab,2011,96(1):19-30.
21 Feng C,Gao Y,Wang C,et al.Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer[J].J Clin Endocrinol Metab,2013,98(9):1524-1533.
22 Grabellus F,Worm K,Schmid KW,et al.The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 over expression[J].Thyroid,2012,22(4):377-382.
23 Zerilli M,Zito G,Martorana A,et al.BRAF(V600E)mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer[J].Mod Pathol,2010,23(8):1052-1060.
24 Kim TH,Park YJ,Lim JA,et al.The association of the BRAF(V600E)mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer:a meta-analysis[J].Cancer,2012,118(7):1764-1773.
25 Liu C,Chen T,Liu Z.Associations between BRAF(V600E)and prognostic factors and poor outcomes in papillarythyroid carcinoma:a meta-analysis[J].Word J Surg Oncol,2016,14(1):241.
26 Kim MH,Ko SH,Bae JS,et al.Non FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma[J].Thyroid,2013,23(11):1452-1460.

[1]	李雪蓉, 冯洪燕, 周莹, 李超群, 兰晓莉, 卜丽红. 比较¹⁸F-FDG PET/CT显像IHP、Deauville和△SUVmax在恶性淋巴瘤早中期治疗敏感性判定和预后评估中的应用价值[J]. 实用肿瘤学杂志, 2019, 33(2): 160-166.
[2]	李仕亮,徐雷,邵国安,孙纷纷,孙林庸,薛军. TRa1基因转录后小片段P28、P43在甲状腺乳头状癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2017, 31(4): 294-298.
[3]	王英炜王宏达朱宏. CK19, HBME-1和MIB-1在甲状腺透明变梁状肿瘤与甲状腺乳头状癌中的表达情况以及鉴别诊断价值[J]. 实用肿瘤学杂志, 2014, 28(4): 326-330.
[4]	王丽, 柏晗, 李文辉. ¹⁸F-FDG PET/CT在非小细胞肺癌精确放疗中的应用[J]. 实用肿瘤学杂志, 2012, 26(3): 272-275.
[5]	于家伟, 管强, 孔令宇, 张杰武. Fascin蛋白在甲状腺乳头状癌中的表达及其临床意义[J]. 实用肿瘤学杂志, 2011, 25(2): 129-132.
[6]	苗素生, 孙冀, 裴荣, 毛雄辉. RET与VEGF-C在甲状腺乳头状癌中表达的研究[J]. 实用肿瘤学杂志, 2010, 24(4): 373-377.
[7]	孙洁, 关海霞, 王立瑶, 王翠芳. Twist及E-cadherin在甲状腺乳头状癌中的表达及其临床病理意义[J]. 实用肿瘤学杂志, 2009, 23(4): 342-345.
[8]	张喜军综述, 张杰武审校. VEGF-C及其与甲状腺乳头状癌关系的研究进展[J]. 实用肿瘤学杂志, 2009, 23(1): 89-90.
[9]	何晓燕;何雪云;郑俊. 甲状腺乳头状癌中PCNA的表达及意义[J]. 实用肿瘤学杂志, 2008, 22(03): 263-264.
[10]	胡贤杰;郭贵龙;顾馨;钟国平;许中友. COX-2的表达与甲状腺乳头状癌中淋巴管生成及淋巴结转移的关系[J]. 实用肿瘤学杂志, 2008, 22(02): 104-107.

甲状腺乳头状癌¹⁸F-FDG PET/CT显像葡萄糖代谢与BRAF突变的相关性研究

The correlation between glucose metabolism and BRAF mutation in ¹⁸F-FDG PET/CT imaging of papillary thyroid carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价